Product Program year 2024 Source: CMS Open Payments

Contrave

Drug Obesity

NDC 51267-890-99

Open in the dashboard

General payments

$1,015,421

49,786 payments

Research payments

$5,647,346

1,108 payments

Through program year 2024, $1,015,421 in general payments and $5,647,346 in research payments were reported against Contrave (Obesity).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Amount Payments
2024 General $211,263 7,181
2024 Research $5,647,346 1,108
2023 General $191,732 9,379
2022 General $175,976 10,670
2021 General $276,609 12,720
2020 General $86,628 4,998
2019 General $73,212 4,838

Breakdown

Who paid General payments · program years 2019–2024
  1. Currax Pharmaceuticals LLC $961,763 46,137 payments
  2. Nalpropion Pharmaceuticals LLC $53,658 3,649 payments
Top recipients General payments · program year 2024
  1. Angela Fitch Obesity Medicine · Boston, MA $17,004 8% · 14 payments
  2. Anthony Auriemma Family Medicine · Westmont, IL $9,619 5% · 18 payments
  3. Caroline Apovian Internal Medicine · Boston, MA $9,503 4% · 4 payments
  4. Ethan Lazarus Family Medicine · Denver, CO $9,329 4% · 11 payments
  5. Donna Ryan Internal Medicine · Baton Rouge, LA $9,002 4% · 7 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Internal Medicine $73,251 35% · 637 practitioners
  2. Family Medicine $47,578 23% · 1,001 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $26,716 13% · 811 practitioners
  4. Obesity Medicine Internal Medicine $17,261 8% · 9 practitioners
  5. Physician Assistant $8,195 4% · 310 practitioners

The top 5 of 90 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. Massachusetts $33,221 16% · 24 recipients
  2. Illinois $30,031 14% · 176 recipients
  3. New York $15,248 7% · 286 recipients
  4. Texas $14,605 7% · 652 recipients
  5. California $12,972 6% · 233 recipients

The top 5 of 47 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

220

Prescriptions dispensed, refills included

Drug cost

$142,088

Paid at the pharmacy, in all

Prescribers

17

With 11 or more claims of it

Medicare Part D drugs matched to CONTRAVE, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Contrave Naltrexone Hcl/Bupropion Hcl Same name 17 220 $142,088

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 17 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Laura Russo Herrera Internal Medicine CA 19 $14,225 None on record
Caitlan Tucker Physician Assistant SC 18 $9,698 None on record
Anwar Khan Internal Medicine FL 17 $10,004 None on record
Nazish Ekram Internal Medicine IL 13 $11,830 $66
Carol Brittsan Physician Assistant SC 13 $10,173 $33

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 17 in the dashboard with a free account
49,786 general · 1,108 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record